6 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will publish its results for the first half of 2022, on September 19, 2022, after market close.
ADOCIA’s management team will organize a webinar on Tuesday, September 20 at 6 p.m. CEST to present its financial results and the progress of its main programs.
The conference will be held in French.
The conference will be moderated by:
• Gérard Soula, CEO and co-founder of Adocia
• Olivier Soula, Deputy CEO-R&D Director and co-founder of Adocia
• Valérie Danaguezian, Administrative and Financial Director
Registration for the videoconference is available at the following link
https://zoom.us/j/92077518485 / Meeting ID: 920 7751 8485
Participants will be able to submit their questions via the chat available during the event. It is also possible to ask questions in advance, by sending them to: [email protected]
The replay of the webinar will be available on the Adocia website in the Investors section:
https://www.adocia.com/en/investors/